T. Blankenstein

822 total citations
16 papers, 707 citations indexed

About

T. Blankenstein is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, T. Blankenstein has authored 16 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 9 papers in Oncology and 5 papers in Genetics. Recurrent topics in T. Blankenstein's work include Immunotherapy and Immune Responses (8 papers), Immune Cell Function and Interaction (7 papers) and CAR-T cell therapy research (6 papers). T. Blankenstein is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Immune Cell Function and Interaction (7 papers) and CAR-T cell therapy research (6 papers). T. Blankenstein collaborates with scholars based in Germany, Sweden and Denmark. T. Blankenstein's co-authors include Zhihai Qin, Gabriele Noffz, Mariette Mohaupt, Hanno Hock, T Diamantstein, Marion Dorsch, Ulrich Kunzendorf, S Cayeux, Bernd Dörken and Max Petersson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

T. Blankenstein

16 papers receiving 698 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T. Blankenstein Germany	9	589	306	152	107	41	16	707
E Aruga United States	8	484 0.8×	283 0.9×	231 1.5×	80 0.7×	24 0.6×	9	646
Gabriele Noffz Germany	8	511 0.9×	243 0.8×	149 1.0×	63 0.6×	30 0.7×	9	624
Tomohiro Kodama Japan	7	456 0.8×	228 0.7×	142 0.9×	75 0.7×	23 0.6×	11	631
Korina G. Veenstra United States	6	317 0.5×	216 0.7×	139 0.9×	54 0.5×	38 0.9×	8	484
Stefan Thoma Germany	10	359 0.6×	133 0.4×	113 0.7×	85 0.8×	30 0.7×	15	515
Kim McKall-Faienza Canada	8	769 1.3×	217 0.7×	165 1.1×	99 0.9×	52 1.3×	11	888
Marie‐Christine Pandolfino France	16	632 1.1×	488 1.6×	155 1.0×	96 0.9×	20 0.5×	29	753
Jill A. Hendrzak United States	7	315 0.5×	152 0.5×	112 0.7×	61 0.6×	21 0.5×	7	432
D. Carbone United States	9	261 0.4×	231 0.8×	230 1.5×	51 0.5×	53 1.3×	15	530
Masataka Nakamura Japan	8	338 0.6×	168 0.5×	78 0.5×	62 0.6×	29 0.7×	10	452

Countries citing papers authored by T. Blankenstein

Since Specialization

Citations

This map shows the geographic impact of T. Blankenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Blankenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Blankenstein more than expected).

Fields of papers citing papers by T. Blankenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Blankenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Blankenstein. The network helps show where T. Blankenstein may publish in the future.

Co-authorship network of co-authors of T. Blankenstein

This figure shows the co-authorship network connecting the top 25 collaborators of T. Blankenstein. A scholar is included among the top collaborators of T. Blankenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Blankenstein. T. Blankenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Pohla, Heike, Gerald Willimsky, Bernhard Frankenberger, et al.. (2010). Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma. MDC Repository (Max-Delbrueck-Center for Molecular Medicine). 4 indexed citations

2.

Westermann, Jörg, Günther Richter, Oliver Schmetzer, et al.. (2004). Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization. Gene Therapy. 11(13). 1048–1056. 17 indexed citations

3.

Hokland, Marianne, Mikkel Steen Petersen, Candace C. Fleischer, et al.. (2004). Monitoring in vivo T cell traficking to tumors by positron emission tomography and magnetic resonance imaging. Journal of Clinical Oncology. 22(14_suppl). 2571–2571. 1 indexed citations

4.

Hokland, Marianne, Mikkel Steen Petersen, Candace C. Fleischer, et al.. (2004). Monitoring in vivo T cell traficking to tumors by positron emission tomography and magnetic resonance imaging. Journal of Clinical Oncology. 22(14_suppl). 2571–2571. 1 indexed citations

5.

Merz, Hartmut, et al.. (2003). [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].. PubMed. 87. 224–31. 6 indexed citations

6.

Schendel, D. J., Bernhard Frankenberger, S Cayeux, et al.. (2000). Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Therapy. 7(23). 2007–2014. 33 indexed citations

7.

Westermann, Jörg, Alexandra Aicher, Zhihai Qin, et al.. (1998). Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation. Gene Therapy. 5(2). 264–271. 48 indexed citations

8.

Qin, Zhihai, Gabriele Noffz, Mariette Mohaupt, & T. Blankenstein. (1997). Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. The Journal of Immunology. 159(2). 770–776. 166 indexed citations

9.

Salazar‐Onfray, Flavio, Jehad Charo, Max Petersson, et al.. (1997). Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. The Journal of Immunology. 159(7). 3195–3202. 75 indexed citations

10.

Daniel, Peter T., Arne Kroidl, S Cayeux, et al.. (1997). Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. The Journal of Immunology. 159(8). 3808–3815. 71 indexed citations

11.

Westermann, Jörg, Alexandra Aicher, Zhaojie Qin, et al.. (1997). Dendritic cells for autologous tumor vaccination in chronic myeloid leukemia. European Journal of Cancer. 33. S30–S30. 1 indexed citations

12.

Salazar‐Onfray, Flavio, Max Petersson, Lars Franksson, et al.. (1995). IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression.. The Journal of Immunology. 154(12). 6291–6298. 64 indexed citations

13.

Blaese, Michael, T. Blankenstein, Malcolm K. Brenner, et al.. (1995). European school of Oncology position paper. Gene therapy for the medical oncologist. European Journal of Cancer. 31(9). 1531–1537. 4 indexed citations

14.

Qin, Zhihai & T. Blankenstein. (1995). Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response.. PubMed. 55(21). 4747–51. 21 indexed citations

15.

Hock, Hanno, Marion Dorsch, Ulrich Kunzendorf, et al.. (1993). Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.. Proceedings of the National Academy of Sciences. 90(7). 2774–2778. 188 indexed citations

16.

Tartakovsky, Boris, et al.. (1989). Correlation between the biologic functions and the generation of lymphokines in T cell clones.. The Journal of Immunology. 142(8). 2695–2701. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact